dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
    • Dr. Friedrich von Bohlen
    • Prof. Dr. Christof Hettich
    • Dr. Mathias Hothum
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch
dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
    • Dr. Friedrich von Bohlen
    • Prof. Dr. Christof Hettich
    • Dr. Mathias Hothum
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch
  • Home
  • CompanyHeidelberg Pharma AG

June 28, 2022: Heidelberg Pharma AG

Heidelberg Pharma Reports Outcome of the Annual General Meeting 2022

Heidelberg Pharma AG announced that the shareholders of the Company approved the resolutions of the administration with large majorities (ranged from 98.49% to 99.99%) during the virtual Annual General Meeting today:

Please read the whole article here

Heidelberg Pharma AG, News 2022

June 28, 2022: Cosmo Pharmaceuticals NV

Cosmo announces acceptance of NDA submission of Cortiment® MMX® in Japan

Cosmo Pharmaceuticals N.V. (“Cosmo”) announced that Ferring, our partner for Cortiment® MMX® (budesonide), submitted the NDA for Japan on June 23, 2022, and the application has been accepted by PMDA (Pharmaceuticals and Medical Devices Agency). The review is expected to last approximately a year.

Please read the whole article here

Cosmo Pharmaceuticals NV, News 2022

June 24, 2022: AC Immune SA

AC Immune Holds Annual General Meeting of Shareholders

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held its Annual General Meeting per Swiss law. Shareholders cast their votes through the independent proxy appointed by the shareholders.

Please read the whole article here
AC Immune SA, News 2022

June 22, 2022: CureVac AG

CureVac Announces Voting Results of General Meeting

CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company’s annual general meeting.

Please read the whole article here

CureVac AG, News 2022

June 16, 2022: AC Immune SA

AC Immune Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

Crenezumab did not statistically significantly slow or prevent cognitive decline in people
with a specific genetic mutation which causes early-onset Alzheimer’s disease

Numerical differences favouring crenezumab over placebo were observed across the co-primary,
multiple secondary and exploratory endpoints

Initial data will be presented at the Alzheimer’s Association International Conference (AAIC) on
August 2, 2022

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced results from the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease (ADAD) Colombia Trial. The study evaluated the potential of crenezumab, an investigational medicine, to slow or prevent Alzheimer’s disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimer’s disease.

Please read the whole article here

AC Immune SA, News 2022

June 8, 2022: CureVac AG

CureVac Announces Changes of CDO – Myriam Mendila to succeed Klaus Edvardsen

  • Myriam Mendila appointed as Chief Development Officer starting from February 1, 2023
  • Klaus Edvardsen returning to Denmark after holding numerous leadership positions in the U.S. and Europe
  • Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim Chief Development Officer

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”) today announced that Chief Development Officer Klaus Edvardsen will leave the company on June 30, 2022. He plans to return home to Denmark for a new professional opportunity. CureVac is pleased to welcome Myriam Mendila to this key role. Myriam’s appointment will take effect on February 1, 2023. Until then, Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim Chief Development Officer.

Please read the whole article here

CureVac AG, News 2022

June 8, 2022: CureVac AG

CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform

  • Acquisition extends CureVac’s capabilities and adds key competencies to further accelerate oncology strategy for new therapies that enable patients’ immune systems to fight cancer
  • Frame’s platform offers potential to develop off-the-shelf and personalized cancer vaccines targeting novel families of neoantigens

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced its acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types.

Please read the whole article here

CureVac AG, News 2022

June 7, 2022: Immatics Biotechnologies GmbH

Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer

Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the two companies have entered into a strategic research collaboration and licensing agreement to combine gamma-delta T cell adoptive cell therapies and gene editing to develop medicines for the treatment of cancer. As part of the licensing agreement, Immatics gains non-exclusive rights to Editas Medicine’s CRISPR technology and intellectual property. Editas Medicine is the exclusive licensee of Harvard and Broad Institute’s Cas9 patent estates and Broad Institute’s Cas12a patent estate for human medicines.

Please read the whole article here

Immatics Biotechnologies GmbH, News 2022

June 2, 2022: Immatics Biotechnologies GmbH

Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs

Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Bristol Myers Squibb (NYSE:BMY), today announced that they have expanded their strategic alliance to pursue the development of multiple allogeneic off-the-shelf TCR-T and/or CAR-T programs.

Please read the whole article here

Immatics Biotechnologies GmbH, News 2022

June 2, 2022: Immatics Biotechnologies GmbH

Immatics Announces First Quarter 2022 Financial Results and Business Update

Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today reported financial results and provided a business update for the quarter ended March 31, 2022.

Please read the whole article here
Immatics Biotechnologies GmbH, News 2022
Older Entries
  • News 2022
  • News 2021
  • News 2020
  • News 2019
  • News 2018
  • General
  • Company
    • AC Immune SA
    • Apogenix AG
    • Cosmo Pharmaceuticals NV
    • CureVac AG
    • Heidelberg Pharma AG
    • Immatics Biotechnologies GmbH
    • Joimax GmbH
    • Molecular Health GmbH
    • Novaliq GmbH

dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz